In this microsimulation modeling study, it was estimated that primary hrHPV screening may represent a reasonable balance of harms and benefits when performed every 5 years. Switching from cytology to hrHPV testing at age 30 years yielded the most efficient harm to benefit ratio when using colposcopy as a proxy for harms.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: